Search clinical trials for: CT053PTSA

Total 5 results

Sunshine Lake Pharma Co., Ltd.

Completed

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sunshine Lake Pharma Co., Ltd.

Terminated

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Advanced NSCLC
Sunshine Lake Pharma Co., Ltd.

Terminated

A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

Renal Cell Cancer Metastatic

China
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Non-small Cell Lung Cancer

China

3

Subscribe